Related Experiment Video
Updated: Jun 4, 2026
Robust Detection of Gene Amplification in Formalin-Fixed Paraffin-Embedded Samples by Fluorescence In Situ Hybridization
Published on: July 12, 2024
Gene Amplification of c-erbB-2 Detected by FISH
1Department of Obstetrics and Gynecology, University of South Carolina School of Medicine, Columbia, SC.
Abstract:
In 1981, a novel transforming gene called neu, related to, but distinct from, the c-erbB protooncogene, was identified (1-3). In 1985, two groups independently isolated identical erbB-related genes from human DNA that they called HER-2 (4) and c-erbB-2 (5) located at chromosome band 17q11.2 and encoding a 185,000 Dalton tyrosine kinase (2,4). Studies conducted on human breast cancers showed 28% to have amplified HER2/neu present (7) and it was suggested that amplification or increased protein expression might confer a selective advantage (6). Over the last ten years, many studies have confirmed the value of using overexpression or amplification of the HER2/neu gene as a predictor of poor outcome in cases of breast cancer (7-9). Clinical trials are currently underway using anti-HER2/neu in an attempt to destroy malignant breast cells (10,11).
Insights
The HER2/neu gene, identified in 1981, is crucial in breast cancer. Amplification of this gene predicts poor outcomes and is a target for new cancer therapies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The neu gene, related to c-erbB, was identified in 1981.
- The HER2/neu gene (also known as c-erbB-2) was isolated from human DNA in 1985, located on chromosome 17q11.2.
- This gene encodes a 185,000 Dalton tyrosine kinase protein.
Purpose of the Study:
- To investigate the role of HER2/neu gene amplification in breast cancer.
- To establish HER2/neu as a prognostic marker for breast cancer.
- To explore therapeutic strategies targeting the HER2/neu gene.
Main Methods:
- Gene identification and isolation.
- Analysis of HER2/neu amplification in human breast cancer tissues.
- Correlation of HER2/neu amplification with patient outcomes.
Main Results:
- Amplification of the HER2/neu gene was found in 28% of human breast cancers.
- HER2/neu amplification or overexpression is a validated predictor of poor prognosis in breast cancer.
- Ongoing clinical trials are investigating anti-HER2/neu therapies.
Conclusions:
- The HER2/neu gene plays a significant role in breast cancer development and progression.
- HER2/neu amplification serves as a critical biomarker for identifying patients with a poor prognosis.
- Targeting HER2/neu represents a promising therapeutic avenue for breast cancer treatment.
